Tumor necrosis factor receptor‐2 signaling pathways promote survival of cancer stem‐like CD133+ cells in clear cell renal carcinoma

Autor: John R. Bradley, Jun Wang, Simon Pacey, Anne Y. Warren, Jordan S. Pober, Rafia S. Al‐Lamki

Publikováno v: FASEB BioAdvances, Vol 2, Iss 2, Pp 126-144 (2020)

Abstract Clear cell renal cell carcinoma (ccRCC) contains cancer stem‐like cells (CSCs) that express CD133 (ccRCC‐CD133+). CSCs are rarely in cell cycle and, as nonproliferating cells, resist most chemotherapeutic agents. Previously, we reported

Externí odkaz: https://doaj.org/article/d5953b34895e4de6b93851e80efc1895

Tumor necrosis factor receptor-2 signaling pathways promote survival of cancer stem-like CD133

Autor: John R, Bradley, Jun, Wang, Simon, Pacey, Anne Y, Warren, Jordan S, Pober, Rafia S, Al-Lamki

Publikováno v: FASEB bioAdvances

Clear cell renal cell carcinoma (ccRCC) contains cancer stem‐like cells (CSCs) that express CD133 (ccRCC‐CD133+). CSCs are rarely in cell cycle and, as nonproliferating cells, resist most chemotherapeutic agents. Previously, we reported that tumo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e72963c31ab971ff841e009fa9048405
https://pubmed.ncbi.nlm.nih.gov/32123862

Efeito da pentoxifilina nas vias canônica e não canônica do NF-kB determinantes de resposta inflamatória em modelos suscetíveis ou não à malária cerebral

Autor: Couto, Shirley Claudino Pereira

Publikováno v: Repositório Institucional da UnB
Universidade de Brasília (UnB)
instacron:UNB

Tese (doutorado) — Universidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Medicina Tropical, 2021. Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). A pentoxifilina (Ptx) tem ação pleiotrópica sob

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3056::134af75887692025564498cad157137b
https://repositorio.unb.br/handle/10482/43388

Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma

Autor: Rafia S, Al-Lamki, Jun, Wang, Jun, Yang, Natalie, Burrows, Patrick H, Maxwell, Timothy, Eisen, Anne Y, Warren, Sakari, Vanharanta, Simon, Pacey, Peter, Vandenabeele, Jordan S, Pober, John R, Bradley

Publikováno v: Oncotarget

Compared to normal kidney, renal clear cell carcinomas (ccRCC) contain increased numbers of interstitial, non-hematopoietic CD133+cells that express stem cell markers and exhibit low rates of proliferation. These cells fail to form tumors upon transp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4f59a1d3399889357156b8504bee521b
https://pubmed.ncbi.nlm.nih.gov/26992212

Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma.

Autor: Al-Lamki RS; Department of Medicine, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge CB2 0QQ, UK., Wang J; Department of Medicine, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge CB2 0QQ, UK., Yang J; Department of Medicine, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge CB2 0QQ, UK., Burrows N; School of Clinical Medicine, Cambridge Institute of Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0XY, UK., Maxwell PH; School of Clinical Medicine, Cambridge Institute of Medical Research, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0XY, UK., Eisen T; Department of Oncology, University of Cambridge, Cambridge CB2 0QQ, UK., Warren AY; Department of Pathology, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK., Vanharanta S; MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Cambridge CB2 0XZ, UK., Pacey S; Department of Oncology, University of Cambridge, Cambridge CB2 0QQ, UK., Vandenabeele P; VIB Inflammation Research Center, Ghent University, UGhent-VIB Research Building FSVM, 9052 Ghent, Belgium., Pober JS; Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06520-8089, USA., Bradley JR; Department of Medicine, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge CB2 0QQ, UK.

Publikováno v: Oncotarget [Oncotarget] 2016 Apr 26; Vol. 7 (17), pp. 24111-24.